Recent Updates
Recently added Catalysts

Fixed

Phase 3

Hypertension | Small molecule | Cardiovascular |Tango Therapeutics, Inc.|Last Updated: Jul 25, 2024

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment532
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05820880Efficacy and Safety of Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg Fixed Combination in HypertensionPHASE3 COMPLETED 532May 6, 2019Feb 23, 2022Jul 25, 202442 China
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Sitting SBP change after two months of treatment
Baseline safety visit, Month 2 follow-up visit

Office sitting Systolic Blood Pressure (SBP) change from baseline to last post-baseline value over the period from Month 0 to month 2

Secondary Endpoints
Sitting SBP change from month 2 to month 4
Month 2 follow-up visit, Month 4 follow-up visit
Sitting SBP change from month 4 to month 6
Month 4 follow-up visit, Month 6 follow-up visit
Sitting DBP change after two months of treatment
Baseline safety visit, Month 2 follow-up visit
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Fixed [Per/Ind/Aml]EXPERIMENTALFrom inclusion to Month 2, patients receive the fixed combination of perindopril 5 mg / indapamide 1.25 mg / amlodipine 5 mg (S06593). From Month 2 to 4, patients either stay at the same dose if the blood pressure is controlled, either are up-titrated to the next dose of the strategy if the blood pressure is not controlled (ie, perindopril 10 mg / indapamide 2.5 mg / amlodipine 5 mg). From Month 4 to 6, patients either stay at the same dose if the blood pressure is controlled, either are up-titrated to the next dose of the strategy if the blood pressure is not controlled (ie, for patients who were up-titrated at Month 2 visit: perindopril 10 mg / indapamide 2.5 mg / amlodipine 10 mg or for patients who were not yet up-titrated: perindopril 10 mg / indapamide 2.5 mg / amlodipine 5 mg.
Free [Per/Ind + Aml]ACTIVE_COMPARATORFrom inclusion to Month 2, patients receive the free combination of perindopril 4 mg / indapamide 1.25 mg plus amlodipine 5 mg. From Month 2 to 4, patients either stay at the same dose if the blood pressure is controlled, either are up-titrated to the next dose of the strategy if the blood pressure is not controlled (ie, double dose of perindopril 4 mg / indapamide 1.25 mg plus amlodipine 5 mg for patients). From Month 4 to 6, patients either stay at the same dose if the blood pressure is controlled, either are up-titrated to the next dose of the strategy if the blood pressure is not controlled (ie for patients who were up-titrated at Month 2 visit: double dose of perindopril 4 mg / indapamide 1.25 mg plus double dose of amlodipine 5 mg or for patients who were not yet up-titrated:double dose of perindopril 4 mg / indapamide 1.25 mg plus amlodipine 5 mg.
Interventions
NameTypeDescription
Fixed [Per/Ind/Aml]DRUGFixed Dose combination of Perindopril/Indapamide/Amlodipine
Free [Per/Ind + Aml]DRUGFree dose combination of Perindopril/Indapamide and Amlodipine
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites42

Main Inclusion Criteria: * Men or women of Asian origin * ≥18 years old * Treated for essential hypertension * Having the day of the selection visit an uncontrolled hypertension treated with any anti-hypertensive monotherapy at maximal dose or any dual therapy at starting dose according to investig...

Countries:China
Unlock Eligibility Criteria